Oral propranolol therapy in parotid hemangiomas: A retrospective comparison with other infantile hemangiomas.
efficacy
parotid hemangioma
propranolol
relapse
treatment duration
Journal
Head & neck
ISSN: 1097-0347
Titre abrégé: Head Neck
Pays: United States
ID NLM: 8902541
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
24
11
2020
received:
29
05
2020
accepted:
15
01
2021
pubmed:
5
2
2021
medline:
1
7
2021
entrez:
4
2
2021
Statut:
ppublish
Résumé
The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites. Patients with IHs treated with oral propranolol were retrospectively reviewed. Outcomes of propranolol therapy for parotid hemangiomas and other IHs were examined. Regression models were conducted to analyze the factors associated with the outcomes for parotid hemangiomas. Longer treatment duration was needed for parotid hemangiomas (p = 0.012) at a comparable efficacy and relapse rate as those of IHs at other sites. The higher efficacy was associated with early intervention before 4 months of age (OR = 5.2, p = 0.011), while, the lower relapse rate was associated with adequate treatment duration over 6 months (OR = 9.2, p = 0.010). With a longer propranolol treatment duration, parotid hemangiomas could achieve a comparable efficacy and relapse rate as other IHs. Early treatment initiation and adequate treatment duration benefited the outcomes.
Sections du résumé
BACKGROUND
The outcomes of propranolol treatment remain controversial for parotid hemangiomas, which may be inferior to outcomes for infantile hemangiomas (IHs) at other sites.
METHODS
Patients with IHs treated with oral propranolol were retrospectively reviewed. Outcomes of propranolol therapy for parotid hemangiomas and other IHs were examined. Regression models were conducted to analyze the factors associated with the outcomes for parotid hemangiomas.
RESULTS
Longer treatment duration was needed for parotid hemangiomas (p = 0.012) at a comparable efficacy and relapse rate as those of IHs at other sites. The higher efficacy was associated with early intervention before 4 months of age (OR = 5.2, p = 0.011), while, the lower relapse rate was associated with adequate treatment duration over 6 months (OR = 9.2, p = 0.010).
CONCLUSIONS
With a longer propranolol treatment duration, parotid hemangiomas could achieve a comparable efficacy and relapse rate as other IHs. Early treatment initiation and adequate treatment duration benefited the outcomes.
Substances chimiques
Propranolol
9Y8NXQ24VQ
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1553-1562Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Esposito C, Zupi A, Califano L. Surgical therapy of parotid hemangiomas. Pediatr Surg Int. 2001;17:335-337.
Greene AK, Rogers GF, Mulliken JB. Management of parotid hemangioma in 100 children. Plast Reconstr Surg. 2004;113(1):53-60.
Léauté-Labrèze C, Harper JI, Hoeger PH. Infantile haemangioma. Lancet. 2017;390(10089):85-94.
Weiss I, O TM, Lipari BA, Meyer L, Berenstein A, Waner M. Current treatment of parotid hemangiomas. Laryngoscope. 2011;121(8):1642-1650.
Krowchuk DP, Frieden IJ, Mancini AJ, et al. Clinical Practice Guideline for the Management of Infantile Hemangiomas. Pediatrics. 2019;143:e20183475.
Brandling-Bennett HA, Metry DW, Baselga E, et al. Infantile Hemangiomas with unusually prolonged growth phase: a case series. Arch Dermatol. 2008;144(12):1632-1637.
Sinno H, Thibaudeau S, Coughlin R, Chitte S, Williams B. Management of infantile parotid gland hemangiomas: a 40-year experience. Plast Reconstr Surg. 2010;125(1):265-273.
Metry DW, Heber AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol. 2000;136:905-914.
Dong JY, Ning JX, Li K, et al. Analysis of factors affecting the therapeutic effect of propranolol for infantile haemangioma of the head and neck. Sci Rep. 2017;7:342.
Zhang L, Yuan WE, Zheng JW. Pharmacological therapies for infantile hemangiomas: a clinical study in 853 consecutive patients using a standard treatment algorithm. Sci Rep. 2016;6:21670.
Bagazgoitia L, Torrelo A, Gutierrez JC, et al. Propranolol for infantile hemangiomas. Pediatr Dermatol. 2011;28(2):108-114.
ISSVA Classification for vascular anomalies. http://wwwissvaorg/UserFiles/file/ISSVA-Classification-2018.
Chen ZY, Wang QN, Zhu YH, et al. Progress in the treatment of infantile hemangioma. Ann Transl Med. 2019;7(22):692.
Achauer BM, Chang CJ, Vander Kam VM. Management of hemangioma of infancy: review of 245 patients. Plast Reconstr Surg. 1997;99(5):1301-1308.
Holmes WJM, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthet Surg. 2011;64(4):445-451.
Morais P, Magina S, Mateus M, Trindade E, Jesus JM, Azevedo F. Efficacy and safety of propranolol in the treatment of parotid hemangioma. Cutan Ocul Toxicol. 2011;30(3):245-248.
Bauland CG, Luning TH, Smit JM, Zeebregts CJ, Spauwen PH. Untreated hemangiomas: growth pattern and residual lesions. Plast Reconstr Surg. 2011;127(4):1643-1648.
Bruckner AL, Frieden IJ. Hemangiomas of infancy. J Am Acad Dermatol. 2003;48(4):477-493. quiz 94-6.
Couto RA, Maclellan RA, Zurakowski D, Greene AK. Infantile hemangioma: clinical assessment of the involuting phase and implications for management. Plast Reconstr Surg. 2012;130(3):619-624.
Haggstrom AN, Drolet BA, Baselga E, et al. Prospective study of infantile hemangiomas: clinical characteristics predicting complications and treatment. Pediatrics. 2006;118(3):882-887.
Reinisch JF, Kim RY, Harshbarger RJ, Meara JG. Surgical management of parotid hemangioma. Plast Reconstr Surg. 2004;113(7):1940-1948.
Harris J, Phillips JD. Evaluating the clinical outcomes of parotid Hemangiomas in the pediatric patient population. Ear Nose Throat J. 2019;145561319877760. https://doi.org/10.1177/0145561319877760.
Li G, Xu DP, Sun HL, et al. Oral propranolol for parotid infantile hemangiomas. J Craniofac Surg. 2015;26(2):438-440.
Chang L, Jin Y, Lv D, et al. Use of propranolol for parotid hemangioma. Head Neck. 2016;38(Suppl 1):E1730-E1736.
Sans V, de la Roque ED, Berge J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124(3):e423-e431.
Chang LC, Haggstrom AN, Drolet BA, et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360-367.
Bagazgoitia L, Hernandez-Martin A, Torrelo A. Recurrence of infantile hemangiomas treated with propranolol. Pediatr Dermatol. 2011;28(6):658-662.
Szychta P, Stewart K, Anderson W. Treatment of infantile hemangiomas with propranolol: clinical guidelines. Plast Reconstr Surg. 2014;133(4):852-862.